A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?

Child and Adolescent Psychiatry and Mental Health

Volumn 6, Issue , 2012, Pages

  Savill, Nicola ^a   Bushe, Chris J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; Drug safety; Guidelines; NICE; SIGN; Summary of product characteristics

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE;

AGGRESSION; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BRUXISM; CARDIOVASCULAR EFFECT; DEPRESSION; DRUG HYPERSENSITIVITY; DRUG SAFETY; HOSTILITY; HUMAN; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TIC; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 84855507474     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-6-2     Document Type: Article

References (27)

1. Attention Deficit Hyperactivity Disorder Diagnosis and management of ADHD in children, young people and adults: NICE Clinical Guideline 72. 2008, Attention Deficit Hyperactivity Disorder.
2. Polanczyk G, De Lima M, Lessa Horta B, Biederman J, Rohde A. The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. Am J Psychiatry 2007, 164:942-948. 10.1176/appi.ajp.164.6.942, 17541055.
3. National Institute for Health and Clinical Excellence Methylphenidate, atomoxetine and dexamfetamine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13 Technology Appraisal 98 2006, National Institute for Health and Clinical Excellence.
4. McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, De Soysa R, Taylor E, Williams T, Wong ICK. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. British J Psych 2009, 194:273-277.
5. European Commission Notice to Applicants. A Guideline on Summary of Product Characteristics (SmPC). 2009, Revision 2, European Commission.
6. European Medicines Agency Committee for medicinal products for human use (CHMP). Guideline on conduct of pharmacovigilance for medicines used by the paediatric population. 2007, European Medicines Agency.
7. U.S, Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry Development and Use of Risk Minimization Action Plans. 2005, U.S, Department of Health and Human Services Food and Drug Administration.
8. Savill N, Bushe C. A systematic review of the contra-indications in the Summary of Product Characteristics for drugs licensed for ADHD in the UK. Poster presentation at the 16th European Congress of Psychiatry, Nice, France 2008,
9. European Medicines Agency Press Release European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU. 2009, European Medicines Agency Press Release.
10. European Medicines Agency Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. 2009, European Medicines Agency.
11. Scottish Intercollegiate Guidelines Network Management of attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline (number 112) 2009, Scottish Intercollegiate Guidelines Network.
12. electronic Medicines Compendium electronic Medicines Compendium., http://www.medicines.org.uk/EMC/medicine/14482/SPC/Strattera++10mg%2c+18mg%2c+25mg%2c+40mg%2c+60mg+or+80mg+hard+capsules./accessed 30th November 2011
13. electronic Medicines Compendium electronic Medicines Compendium., http://www.medicines.org.uk/EMC/medicine/8382/SPC/Concerta+XL+18+mg+-+36+mg+prolonged+release+tablets/accessed 30th November 2011
14. electronic Medicines Compendium electronic Medicines Compendium., http://www.medicines.org.uk/EMC/medicine/19549/SPC/Concerta+XL+27+mg+prolonged-release+tablets/accessed 30th November 2011
15. electronic Medicines Compendium electronic Medicines Compendium., http://www.medicines.org.uk/EMC/medicine/19510/SPC/Medikinet+XL/accessed 30th November 2011
16. electronic Medicines Compendium electronic Medicines Compendium., http://www.medicines.org.uk/EMC/medicine/1316/SPC/Ritalin/accessed 30th November 2011
17. electronic Medicines Compendium electronic Medicines Compendium., http://www.medicines.org.uk/EMC/medicine/19664/SPC/Medikinet+Tablets/accessed 30th November 2011
18. Dexamfetamine Sulphate 5 mg Tablets, Summary of Product Characteristics, March 2010 Auden Mackenzie.
19. BNFC.org. British National Formulary for Children 2010-2011.
20. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007, 21(1):10-41.
21. Department of Health and Human Services Food and Drug Administration Public Law 110-85. Title V--Best Pharmaceuticals for Children Act of 2007, Food and Drug Administration Amendments Act of 2007. Department of Health and Human Services Food and Drug Administration., http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110.pdf
22. Regulation (EC) No 1901/of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.
23. European Medicines Agency European network of paediatric research. Recognition criteria for self assessment 2010, European Medicines Agency.
24. Bangs M, Sitra T-W, Polzer J, Zhang Shuyu DVM, Acharya N, Desaiah D, Allen AJ. Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine. J Am Acad Child Adolesc Psychiatry 2008, 47(2):209-218. 10.1097/chi.0b013e31815d88b2, 18176331.
25. Waxmonski JG, Waschbusch DA, Pelham WE, Draganac-Cardona L, Rotella B, Ryan L. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2010, 71(11):1535-51. 10.4088/JCP.09m05496pur, 20673557.
26. Martenyi F, Treuer T, Gau SS, Hong SD, Palaczky M, Šuba J, Tiberiu M, Uhli{dotless}kova P, Xu T, Zoroglu S, Gadow KD, Walton R, Harrison G. Attention-deficit/hyperactivity disorder diagnosis, co-morbidities, treatment patterns, and quality of life in a pediatric population in central and eastern Europe and Asia. J Child Adolescent Psychopharmacol 2009, 19(4):363-76.
27. Saylor K, Williams DW, Schuh KJ, Wietecha L, Greenbaum M. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. Curr Med Res Opin 2010, 26(9):2087-95. 10.1185/03007995.2010.493747, 20642391.